Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arctic Bioscience AS ( (DE:9TD) ) has provided an update.
Arctic Bioscience announced that an investor from a consortium has converted NOK 510,000 of debt into shares at a rate of NOK 3.00 per share, following a convertible loan agreement. This conversion increases the company’s total issued shares to 26,859,340, potentially strengthening its financial position and stakeholder confidence.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company specializing in the development and commercialization of pharmaceutical products and dietary supplements derived from unique bioactive marine raw materials. The company is working on HRO350, an oral drug candidate for treating mild-to-moderate psoriasis, and markets dietary supplements globally under the brand ROMEGA®.
YTD Price Performance: 163.91%
Average Trading Volume: 2,000
Technical Sentiment Signal: Buy
Current Market Cap: €10.12M
Learn more about 9TD stock on TipRanks’ Stock Analysis page.